Post-Traumatic Stress Disorder (PTSD) is a mental health condition that can occur in individuals who have experienced traumatic events. While PTSD is primarily addressed through psychotherapy and medications, there is ongoing research and development within the pharmaceutical and healthcare industry to improve treatment options.
Latest Post-Traumatic Stress Disorder Companies UpdateJune 2023: Drugmaker Sanofi called the rival pharmaceutical company's court tab "improper" in a battle over the market for the EpiPen auto-injector device and requested a U.S. judge to limit Mylan's bid to collect legal costs in an antitrust complaint. In a petition in a federal court in Kansas, Sanofi's attorneys at Weil, Gotshal & Manges contended that most of Mylan's request for more than $776,000 in costs, including deposition fees and transcribing services, should be denied. After successfully fending Sanofi's accusations, Mylan—now a part of the Pennsylvania-based healthcare corporation Viatris—requests reimbursement for litigation expenditures. The disagreement will now be heard in federal court, according to the two companies, which claimed they could not agree over costs.List of Post-Traumatic Stress Disorder Key companies in the market
Post Traumatic Stress Disorder Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)